The efficacy of intralymphatic administration of Diamyd®, an antigen specific immunotherapy aimed at stopping the immune systems attack on the beta cells in autoimmune diabetes, is being confirmed in the Phase IIb trial DIAGNODE-2 and in the Phase I/II trial GADinLADA.
Remygen ®, a regenerative and immunomodulatory therapy aimed at stimulating the regrowth of beta cells in patients with autoimmune diabetes, is being evaluated in the Phase I/II trial ReGenerate-1.